Akero Therapeutics Initiates Study of Efruxifermin in NASH/MASH Patients
Akero Therapeutics is conducting a multi-center, randomized, double-blind, placebo-controlled study of efruxifermin in patients with non-cirrhotic NASH/MASH and fibrosis.
Therapeutic Area
Therapeutic area intelligence for NASH with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Boehringer Ingelheim is conducting a trial to evaluate the efficacy of survodutide in adults with NASH or MASH and cirrhosis.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.